Multicell Techs Inc (MCET) 0.0003 $MCET Fatigue Market

New Post Public Reply Private Reply Replies (0) Message Board

Jun 9, 2016 at 8:05 AM

Multicell Techs Inc (MCET) 0.0003 $MCET

Fatigue Market Pipeline H1 2016 Global Research Report
PR Newswire - Tue Apr 05, 5:00AM CDT
New market research titled "Fatigue - Pipeline Review, H1 2016" is a report that provides an overview of worldwide Fatigue therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Global Fatigue Pipeline Review 2015 - 6 Companies & 5 Drug Profiles
M2 - Fri Sep 04, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s5t3hc/fatigue) has announced the addition of the "Fatigue - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fatigue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatigue and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Biovista Inc. - Dimerix Bioscience Pty Ltd - Hemispherx Biopharma, Inc. - Merz Pharmaceuticals GmbH - MultiCell Technologies, Inc. - Teva Pharmaceutical Industries Limited Drug Profiles - (lofepramine hydrochloride phenylalanine) - armodafinil - DMX-400 - MRZ-9547 - rintatolimod - Small Molecule for Chronic Fatigue Syndrome For more information visit http://www.researchandmarkets.com/research/s5t3hc/fatigue
TEVA: 53.99 (-0.07)

Millennium Healthcare Inc. Appoints Anthony Cataldo, CEO of Oxis Biotech, to Board of Advisors
Marketwired - Wed Jun 03, 11:30AM CDT
Millennium Healthcare Inc. (OTCQB: MHCC), a healthcare services and medical device distribution company, today announced that the Company has appointed Anthony (Tony) Cataldo to the Board of Advisors effective June 1, 2015.

MultiCell Immunotherapeutics And Oxis Biotech Sign Antibody-Drug Conjugate R&D, Product License And Commercialization Agreement
PR Newswire - Thu Mar 12, 9:35AM CDT
MultiCell Immunotherapeutics, Inc. (MCIT), a majority owned subsidiary of MultiCell Technologies, Inc. (OTC: MCET) announced today it has signed a research & development and product license agreement with Oxis Biotech, Inc. (OXIS) to create three novel antibody-drug conjugates (ADCs) containing OXIS' lead drug candidates using MCIT's proprietary ADC platform technology. These ADC product candidates are to be used by OXIS for the treatment of triple-negative breast cancer, and multiple myeloma and associated osteolytic lesions which are significant unmet medical needs.

MultiCell Technologies Files Novel Antibody-Drug Conjugate Patent Application
PR Newswire - Wed Dec 10, 7:40AM CST
MultiCell Technologies, Inc. (OTC: MCET) has filed a U.S. patent application covering the design and therapeutic use of novel, next-generation antibody drug conjugates (ADCs) which provide for the simultaneous targeted delivery of multiple drugs from a single antibody.

Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 3.66 (-0.22), AMGN: 158.00 (-0.89), RGLS: 5.31 (-0.15), LLY: 74.91 (+0.21), GSK: 42.51 (-0.19), PVCT: 0.38 (-0.03), CANF: 2.95 (-0.02), DCTH: 0.26 (unch), NVS: 81.39 (-0.22), XLRN: 36.16 (+0.40)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Leidos' Autonomous Vessels Chart Bold Naval Waters

Leidos' Autonomous Leap with the U.S. Navy Well, today it's all about Leidos, an outfit that's been showing its grit in the world of maritime autonomy. Their systems aren't just tinkering around anymore—they're slicing through the waves at RIMPAC, the Rim of the Pacific, and running alongside the USS Theodore Roosevelt Carrier Strike Group. That's big news in anyone's...

Mandeville Pests: Health Dangers Lurking at Home

Pest Trouble Brewing in Mandeville: A Health Alert There’s a storm brewing in Mandeville, Louisiana, and it's not the kind you can see rolling in on the horizon. We're talking about those sneaky pests going unnoticed in our homes. Folks, these pests aren't just a nuisance; they're ticking time bombs for public health. Take it from J&J Exterminating, who know a thing or...

How Timekettle Is Bridging Language Gaps at IFA 2026

Pioneering AI Innovations in Language Translation Timekettle is making some serious waves at IFA 2026, throwing its hat in the ring with innovations that redefine multilingual interaction. From sleek translation earbuds to full-blown meeting hubs, each gadget screams one thing loud and clear—communication sans language barriers. Centered in the tech extravaganza of...

Jollibee and DreamWorks Unite for Cultural Celebration

Jollibee Partners with DreamWorks Animation Never thought I’d see the day: Jollibee, that familiar face of fast food, teaming up with the creative juggernaut DreamWorks Animation. They’re calling it a celebration of friendship and Filipino culture, wrapped up neatly in the context of a flick called Forgotten Island. Set to sizzle in theaters on September 25, 2026,...

Stoke Space Raises $1B; XTEND AI Hits NYSE

A Billion-Dollar Boost for Stoke Space Ever catch wind of a company hauling in a cool billion and shrug it off? Me neither. Stoke Space Technologies just locked down $1 billion in Series E funding. This ain't some pocket change—the kind of dough you need when you're eyeing stars and plotting orbital voyages. They're gearing up for a 2027 mission with their Nova...

Goodwill's ReThink Fashion: Textiles to Runway Art

Transforming Old to New on the Runway Right when you think fashion's all about the next shiny thing, here comes Goodwill of Delaware & Delaware County flipping the script. Their ReThink Fashion Show - the ECO Edit teaches us a thing or two about what giving old clothes a new life truly means. It's not just about tossing a used tee onto a catwalk but a whole rebirth...

AllyGPO Shines as Top Innovator in Health Tech

Innovative Excellence in Healthcare Tech It's not every day you see a specialty group purchasing organization like AllyGPO snagging a spot on Fast Company's esteemed list of Best Workplaces for Innovators. Making it into the top half at number 40 in 2026, it’s a testament to a company really leaning into employee-driven innovation. And, buddy, this ain't just corporate...

AI Startup Shuttlebase Navigates Name Clash with Change

When Two AI Giants Collide Every so often, we get a clash of titans in the business world, and this time it's in the AI universe. New York's Moonshot AI, a champ in autonomous website optimization, hit a bump when its name collided with a Chinese counterpart, also called Moonshot AI. And just like that, the NY company had to chuck their name out the window and don a new...

MADD, Uber Rally at Capital Invitational for Safe Choices

Driving Change at the Capital Invitational Let's talk about a powerhouse collaboration aiming to do more than just thrill basketball fans. We're looking at MADD Sports, Uber, and the Capital Invitational joining forces at The St. James in Springfield, Virginia, on December 10, 2026. This is not your average sporting event; it's a gathering with a bigger purpose. The...

Nashville Benefit Concert Supports Animal Rescue Mission

Country Tunes and Compassion Unite for Rescue Efforts There's something electric about a community banding together, especially when it's through the warmth of country music and the noble mission of animal rescue. Animal Rescue Corps (ARC), meeting ground for art and heart, is turning the Nashville Palace into a sanctuary not just for music, but for hope. They've got...